Ketamine vs Propofol for Sedation During Pediatric Bronchoscopy

Brief Summary

The purpose of this study is to determine whether ketamine or propofol, drugs used for procedural sedation during paediatric bronchoscopy, results in higher operator satisfaction and better side effect profile.

Intervention / Treatment

  • Ketamine (DRUG)
    N/A
  • Propofol (DRUG)
    N/A
  • midazolam and atropine (DRUG)
    N/A
  • Lidocaine (DRUG)
    N/A

Condition or Disease

  • Paediatric Flexible Bronchoscopy

Phase

  • Not Applicable
  • Study Design

    Study type: INTERVENTIONAL
    Status: Suspended
    Study results: No Results Available
    Age: up to 18 Years   (Child, Adult)
    Enrollment: 150 (ESTIMATED)
    Funded by: Other
    Allocation: Randomized
    Primary Purpose: Treatment

    Masking

    DOUBLE:
    • Participant
    • Outcomes Assessor

    Clinical Trial Dates

    Start date: May 01, 2016
    Primary Completion: May 01, 2019 ESTIMATED
    Completion Date: May 01, 2019 ESTIMATED
    Study First Posted: Apr 19, 2016 ESTIMATED
    Results First Posted: Aug 31, 2020
    Last Updated: Apr 27, 2017

    Sponsors / Collaborators

    Lead Sponsor: Rabin Medical Center
    Lead sponsor is responsible party
    Responsible Party: N/A

    Pediatric bronchoscopy requires moderate to deep sedation in order to maintain patient comfort and safety, while optimizing the working environment for the physician performing the procedure. There is a paucity of pediatric research in the field of pediatric flexible bronchoscopy and data are often extrapolated from adult studies.

    Propofol is often used as the sedation drug for this procedure due to its rapid sedative effect and favorable emergence profile. Propofol's major limitation is its tendency to cause apneas, which can occur in a relatively narrow therapeutic window. Apnea risk decreases with the patient's age and administering physician's familiarity and experience with the drug.

    Ketamine is a drug often used for pediatric procedural sedation. Its pharmacologic safety profile is very wide, allowing a wide spectrum of dosing with a significantly reduced risk of apnea when compared to propofol. Known adverse effects of the drug include its emergence profile which may be accompanied by hallucinations, bronchorrhea and laryngospasm. Hallucinations may be prevented by using benzodiazepines concurrently and are possibly more pronounced in teenaged children compared to infants, although post-sedation irritability in the latter group might be an expression of this. Bronchorrhea, while usually not of significant concern during procedural sedation, has the potential to play a more noteworthy role during bronchoscopy. Significant airway secretions can create a difficult working environment for the pulmonologist performing the procedure. Patient safety may also be affected, as increased airway secretions reduce visibility in pediatric airways that are narrow to begin with and further compromised by placement of the bronchoscope. Potentially, this might also impact on the child's air flow and gas exchange. Laryngospasm during the procedure potentially hinders passage of the scope beyond the vocal cords and might extend the duration of the procedure.

    In the investigators' center, propofol has most often been the sedative drug of choice for bronchoscopy. Yet, ketamine has been used at times due to its safety profile and the administering physicians level of comfort with each drug.

    Aim:

    To compare operator satisfaction and adverse effects in children presenting for flexible bronchoscopy using ketamine versus propofol as the primary sedative agent.

    Participant Groups

    • All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg. This study group will be exposed to ketamine as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose.

    • All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg. This study group will be exposed to propofol as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose.

    Eligibility Criteria

    Sex: All
    Maximum Age: 18
    Age Groups: Child / Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    * Children undergoing flexible bronchoscopy

    Exclusion Criteria:

    * Failure to acquire parental consent
    * Bronchoscopies performed outside of the bronchoscopy suite
    * Bronchoscopies performed under general anesthesia with a protected airway
    * Bronchoscopies performed by personnel outside of the study group
    * Known allergies to either of the sedation drugs used

    Primary Outcomes
    • Assessed via visual analog scale

    Secondary Outcomes
    • Assessed via visual analog scale

    • Assessed via visual analog scale

    More Details

    NCT Number: NCT02743104
    Other IDs: KP-001
    Study URL: https://clinicaltrials.gov/study/NCT02743104
    Last updated: Sep 29, 2023